Tel Aviv University’s Prof. Carmit Levy Receives Melanoma Award
Tel Aviv University’s Prof. Carmit Levy was awarded the prestigious Young Investigator Award at the 16th International Congress of the Society for Melanoma Research (SMR), held November 20-23 in Salt Lake City, Utah, for her “contributions to melanoma research that significantly exceeded the average for this career stage.”
Sponsored by the Melanoma Research Foundation, this award is presented to an independent researcher within the first five years of his or her career for discoveries about the mechanisms driving melanoma that have had an undeniable impact on cancer research.
“Melanoma can be devastating, creeping up on a person years after the initial malignancy,” says Prof. Karen Avraham, Vice Dean of TAU’s Sackler School of Medicine. “Prof. Carmit Levy’s research has discovered key elements of melanoma metastasis and is laying the groundwork for future therapies. She continues to bring us at Tel Aviv University great pride for her and her team’s remarkable research in cancer development, and specifically melanoma.”
Prof. Levy’s lab is located at the Department of Human Genetics and Biochemistry at TAU’s Sackler School of Medicine.
“I am profoundly excited and honored to be awarded the Young Investigator Award,” said Prof. Levy after the ceremony. “The Society of Melanoma Research is an international organization that centers around the innovative melanoma research being done worldwide. I began my scientific career attending the SMR conferences with these world leader scientists as my inspiration, and now it is an outstanding professional achievement to be among the eight scientists that have received this award since its establishment, and to be acknowledged for our contribution to melanoma research.
“Upon establishing my lab at Tel Aviv University, we discovered pivotal mechanisms in melanoma metastasis initiation, which now opens horizons for new drugs to be used for prevention. I am proud to contribute to the global effort cancer researchers are making, day and night around the world, to overcome this devastating disease. As I always say, this is hard team work.”
The SMR is an all-volunteer group of scientists working to find the mechanisms responsible for melanoma and, consequently, new therapies for this cancer. SMR contributes to advances in melanoma research by bringing together researchers in a non-competitive way to unite the scientific community.